Search

Your search keyword '"Cheema, Faiqa"' showing total 23 results
Start Over Author "Cheema, Faiqa" Publication Year Range Last 50 years
23 results on '"Cheema, Faiqa"'

1. Non-Lung Solid Organ Transplantation From SARS-CoV-2–Positive Donors to Uninfected Recipients

Author

Wade, Jason, Petitpas, Kaitlyn M., Dar, Wasim, Ali, Ayyaz, Radojevic, Joseph A., Lawlor, Michael T., Hammond, Jonathan A., Gluck, Jason, Feingold, Andrew D., Jaiswal, Abhishek, Ebcioglu, Zeynep, Einstein, Michael, Morgan, Glyn, Emmanuel, Bishoy, Ye, Xiaoyi, Singh, Joseph U., Sotil, Eva U., Swales, Colin, Kent, Rebecca, Richardson, Elizabeth, Cheema, Faiqa, and Serrano, Oscar K.

Published
2023
Full Text
View/download PDF

2. 420.6: Transplantation of Organs From SARS-CoV-2-Positive Donors To Uninfected (Non-lung) Solid Organ Transplant Recipients Has Not Resulted in Significant SARS-CoV-2 Related Morbidity Or Mortality

Author

Dar, Wasim, Wade, Jason, Ali, Ayyaz, Radojevic, Joseph A., Lawlor, Michael T., Hammond, Jonathan A., Gluck, Jason, Feingold, Andrew D., Jaiswal, Abhishek, Ebcioglu, Zeynep, Einstein, Michael, Morgan, Glyn, Emmanuel, Bishoy, Ye, Xiaoyi, Singh, Joseph, Sotil, Eva U., Swales, Colin, Kent, Rebecca, Richardson, Elizabeth, Tremaglio, Joseph, Cheema, Faiqa, and Serrano, Oscar

Published
2022
Full Text
View/download PDF

8. Implementing a regional standardized BK polyomavirus screening protocol across eleven transplant centres

Author

Rogers, Ralph, primary, Bodziak, Kenneth, additional, Cheema, Faiqa, additional, Chobanian, Michael, additional, Ebcioglu, Zeynep, additional, Gabardi, Steven, additional, Ghai, Sandeep, additional, Gilligan, Hannah, additional, Gohh, Reginald, additional, Goyal, Nitender, additional, Kavalam, George, additional, Mehri, Basma, additional, Rodig, Nancy, additional, Rossi, Ana, additional, Singh, Joseph, additional, Wood, Emily, additional, Tan, Chen Sabrina, additional, and Pavlakis, Martha, additional

Published
2021
Full Text
View/download PDF

11. Evaluation of cytomegalovirus prophylaxis in low and intermediate risk kidney transplant recipients receiving lymphocyte‐depleting induction

Author

Stamps, Hillary, primary, Linder, Kristin, additional, O'Sullivan, David M., additional, Serrano, Oscar K., additional, Rochon, Caroline, additional, Ebcioglu, Zeynep, additional, Singh, Joseph, additional, Ye, Xiaoyi, additional, Tremaglio, Joseph, additional, Sheiner, Patricia, additional, Cheema, Faiqa, additional, and Kutzler, Heather L., additional

Published
2021
Full Text
View/download PDF

13. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut

Author

Kutzler, Heather L., primary, Poulos, Constantine M., additional, Cheema, Faiqa, additional, O’Sullivan, David M., additional, Ali, Ayyaz, additional, Ebcioglu, Zeynep, additional, Einstein, Michael, additional, Feingold, Andrew D., additional, Gluck, Jason, additional, Hammond, Jonathan A., additional, Jaiswal, Abhishek, additional, Lawlor, Michael T., additional, Morgan, Glyn, additional, Radojevic, Joseph A., additional, Rochon, Caroline, additional, Sheiner, Patricia, additional, Singh, Joseph U., additional, Sotil, Eva U., additional, Swales, Colin, additional, Ye, Xiaoyi, additional, and Serrano, Oscar K., additional

Published
2020
Full Text
View/download PDF

14. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections

Author

Warner, Nathaniel C, primary, Bartelt, Luther A, additional, Lachiewicz, Anne M, additional, Tompkins, Kathleen M, additional, Miller, Melissa B, additional, Alby, Kevin, additional, Jones, Melissa B, additional, Carr, Amy L, additional, Alexander, Jose, additional, Gainey, Andrew B, additional, Daniels, Robert, additional, Burch, Anna-Kathryn, additional, Brown, David E, additional, Brownstein, Michael J, additional, Cheema, Faiqa, additional, Linder, Kristin E, additional, Shields, Ryan K, additional, Longworth, Sarah, additional, and van Duin, David, additional

Published
2020
Full Text
View/download PDF

17. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Author

Warner, Nathaniel C, Bartelt, Luther A, Lachiewicz, Anne M, Tompkins, Kathleen M, Miller, Melissa B, Alby, Kevin, Jones, Melissa B, Carr, Amy L, Alexander, Jose, Gainey, Andrew B, Daniels, Robert, Burch, Anna-Kathryn, Brown, David E, Brownstein, Michael J, Cheema, Faiqa, Linder, Kristin E, Shields, Ryan K, Longworth, Sarah, and Duin, David van

Subjects
ANTIBIOTICS, RESEARCH, MEDICAL cooperation, RETROSPECTIVE studies, CYSTIC fibrosis, DISEASE relapse, GRAM-negative bacterial diseases
Abstract

Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. CYP51A polymorphisms of Aspergillus fumigatus in lung transplant recipients: Prevalence, correlation with phenotype, and impact on outcomes.

Author

Henry, Benoît, Guenette, Alexis, Cheema, Faiqa, Pérez-Cortés, Armelle, McTaggart, Lisa, Mazzulli, Tony, Singer, Lianne, Keshavjee, Shaf, Kus, Julianne V, and Husain, Shahid

Abstract

Azole resistance in Aspergillus fumigatus is increasing worldwide and can affect prognosis. It is mostly mediated by cytochrome P51 (CYP51) mutations. In lung transplant recipients (LTR), little is known regarding the prevalence and clinical impact of CYP51 mutations. One hundred thirty-one consecutive A. fumigatus isolates from 103 patients were subjected to CYP51A genotyping through PCR and sequencing. Antifungal susceptibility testing was performed using the Sensititre YeastOne YO-9© broth microdilution technique. Correlations between genotype, phenotype, clinical manifestations of Aspergillus infection, and clinical outcomes were made. Thirty-four (26%) isolates harbored mutations of CYP51A; N248K (n = 14) and A9T (n = 12) were the most frequent. Three isolates displayed multiple point mutations. No significant influences of mutational status were identified regarding azole MICs, the clinical presentation of Aspergillus disease, 1-year all-cause mortality, and clinical outcomes of invasive forms. In the specific context of lung transplant recipients, non-hotspot CYP51A-mutated isolates are regularly encountered; this does not result in major clinical consequences or therapeutic challenges. Lay Summary In 131 isolates of Aspergillus fumigatus isolates originating from 103 lung transplant recipients, the CYP51A polymorphism rate was 26%, mostly represented by N248K and A9T mutations. These mutations, however, did not significantly impact azoles minimal inhibitory concentrations or clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Prediction of Failure in Vancomycin-Treated Methicillin-Resistant Staphylococcus aureusBloodstream Infection: a Clinically Useful Risk Stratification Tool

Author

Moore, Carol L., Lu, Mei, Cheema, Faiqa, Osaki-Kiyan, Paola, Perri, Mary Beth, Donabedian, Susan, Haque, Nadia Z., and Zervos, Marcus J.

Abstract

ABSTRACTMethicillin-resistant Staphylococcus aureus(MRSA) is a common cause of bloodstream infection (BSI) and is often associated with invasive infections and high rates of mortality. Vancomycin has remained the mainstay of therapy for serious Gram-positive infections, particularly MRSA BSI; however, therapeutic failures with vancomycin have been increasingly reported. We conducted a comprehensive evaluation of the factors (patient, strain, infection, and treatment) involved in the etiology and management of MRSA BSI to create a risk stratification tool for clinicians. This study included consecutive patients with MRSA BSI treated with vancomycin over 2 years in an inner-city hospital in Detroit, MI. Classification and regression tree analysis (CART) was used to develop a risk prediction model that characterized vancomycin-treated patients at high risk of clinical failure. Of all factors, the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, with a cutoff point of 14, was found to be the strongest predictor of failure and was used to split the population into two groups. Forty-seven percent of the population had an APACHE-II score < 14, a value that was associated with low rates of clinical failure (11%) and mortality (4%). Fifty-four percent of the population had an APACHE-II score ≥ 14, which was associated with high rates of clinical failure (35%) and mortality (23%). The risk stratification model identified the interplay of three other predictors of failure, including the vancomycin MIC as determined by Vitek 2 analysis, the risk level of the source of BSI, and the USA300 strain type. This model can be a useful tool for clinicians to predict the likelihood of success or failure in vancomycin-treated patients with MRSA bloodstream infection.

Published
2011
Full Text
View/download PDF

23. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut.

Author

Kutzler HL, Poulos CM, Cheema F, O'Sullivan DM, Ali A, Ebcioglu Z, Einstein M, Feingold AD, Gluck J, Hammond JA, Jaiswal A, Lawlor MT, Morgan G, Radojevic JA, Rochon C, Sheiner P, Singh JU, Sotil EU, Swales C, Ye X, and Serrano OK

Subjects
Aged, Aged, 80 and over, Comorbidity, Connecticut epidemiology, Female, Humans, Male, Middle Aged, SARS-CoV-2, COVID-19 epidemiology, Organ Transplantation methods, Transplant Recipients
Abstract

Competing Interests: The authors declare no funding or conflicts of interest.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results